- Home
- CPHC vs SGMT Comparison
CPHC vs SGMT Comparison
Compare CPHC & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPHC
- SGMT
- Stock Information
- Founded
- CPHC 1994
- SGMT 2006
- Country
- CPHC United States
- SGMT United States
- Employees
- CPHC N/A
- SGMT N/A
- Industry
- CPHC Services-Misc. Amusement & Recreation
- SGMT
- Sector
- CPHC Consumer Discretionary
- SGMT
- Exchange
- CPHC Nasdaq
- SGMT Nasdaq
- Market Cap
- CPHC 94.6M
- SGMT 93.7M
- IPO Year
- CPHC 1994
- SGMT 2023
- Fundamental
- Price
- CPHC $19.80
- SGMT $4.50
- Analyst Decision
- CPHC
- SGMT Strong Buy
- Analyst Count
- CPHC 0
- SGMT 5
- Target Price
- CPHC N/A
- SGMT $21.60
- AVG Volume (30 Days)
- CPHC 3.9K
- SGMT 720.9K
- Earning Date
- CPHC 11-07-2024
- SGMT 11-13-2024
- Dividend Yield
- CPHC 1.37%
- SGMT N/A
- EPS Growth
- CPHC N/A
- SGMT N/A
- EPS
- CPHC 0.94
- SGMT N/A
- Revenue
- CPHC $62,111,814.00
- SGMT N/A
- Revenue This Year
- CPHC N/A
- SGMT N/A
- Revenue Next Year
- CPHC N/A
- SGMT N/A
- P/E Ratio
- CPHC $21.65
- SGMT N/A
- Revenue Growth
- CPHC 0.13
- SGMT N/A
- 52 Week Low
- CPHC $14.27
- SGMT $2.39
- 52 Week High
- CPHC $30.25
- SGMT $20.71
- Technical
- Relative Strength Index (RSI)
- CPHC 53.02
- SGMT 40.28
- Support Level
- CPHC $19.47
- SGMT $4.19
- Resistance Level
- CPHC $20.38
- SGMT $6.40
- Average True Range (ATR)
- CPHC 0.56
- SGMT 0.50
- MACD
- CPHC 0.03
- SGMT -0.23
- Stochastic Oscillator
- CPHC 55.10
- SGMT 14.03
About CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).